ArticleWorld journal of clinical cases2022
Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis.
Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Systems-Level Analysis of 13-Docosenamide Reveals its Regulatory Role on PPAR, AMPK, and Insulin Pathways in T2DM: In vitro and In silico Approaches.Cell biochemistry and biophysics · 2026Article
- Combined In Vitro and Computational Investigations on Synthesized Sulfonamide-Based Antidiabetic Agents.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Networking Pharmacology and Integrated Bioinformatic Analysis of Hygrophila Auriculata for Lipid Metabolism Modulation in Type 2 Diabetes Mellitus.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSulfonylurea (SU) is a commonly used antidiabetic drugs effective for type 2 diabetes mellitus. Previous studies have reported that the SU treatment could alter the serum free fatty acid (FFA) concentration in diabetic patients; however, their exact effects remain unknown.
aimTo assess the impact of SU on the FFA level in diabetic patients.
methodsA systematic literature search was conducted by consulting the PubMed, EMBASE, Cochrane Library,
resultsA total of 13 studies with 2273 individuals were selected. Results indicated that FFA concentration increased slightly after treatment with SU (MD = 0.08, 95%CI: 0.03-0.12,
conclusionSU treatment could increase the serum FFA concentration in diabetic patients. The fundamental underlying mechanism still needs further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.